Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1951 2
1953 1
1954 7
1955 2
1956 3
1957 6
1958 7
1959 5
1960 1
1961 7
1962 6
1963 9
1964 8
1965 8
1966 13
1967 10
1968 7
1969 17
1970 11
1971 4
1972 8
1973 10
1974 7
1975 5
1976 10
1977 6
1978 16
1979 8
1980 13
1981 13
1982 12
1983 13
1984 11
1985 10
1986 11
1987 12
1988 24
1989 16
1990 7
1991 11
1992 17
1993 7
1994 17
1995 8
1996 13
1997 18
1998 13
1999 19
2000 21
2001 26
2002 23
2003 21
2004 21
2005 16
2006 15
2007 13
2008 15
2009 12
2010 19
2011 22
2012 17
2013 20
2014 26
2015 23
2016 22
2017 23
2018 22
2019 9
2020 20
2021 19
2022 31
2023 18
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

906 results

Results by year

Filters applied: . Clear all
Page 1
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Gastaldelli A, et al. Among authors: bray r. Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406. doi: 10.1016/S2213-8587(22)00070-5. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468325 Clinical Trial.
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Ludvik B, et al. Among authors: bray r. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370970 Clinical Trial.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA. Frias JP, et al. Among authors: bray r. Diabetes Obes Metab. 2020 Jun;22(6):938-946. doi: 10.1111/dom.13979. Epub 2020 Feb 11. Diabetes Obes Metab. 2020. PMID: 31984598 Free PMC article. Clinical Trial.
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Battelino T, Bergenstal RM, Rodríguez A, Fernández Landó L, Bray R, Tong Z, Brown K. Battelino T, et al. Among authors: bray r. Lancet Diabetes Endocrinol. 2022 Jun;10(6):407-417. doi: 10.1016/S2213-8587(22)00077-8. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468321 Clinical Trial.
From antigens to eplets: The evolution of HLA.
Gebel HM, Norin AJ, Bray RA. Gebel HM, et al. Among authors: bray ra. Hum Immunol. 2022 Mar;83(3):197-198. doi: 10.1016/j.humimm.2022.01.012. Epub 2022 Feb 5. Hum Immunol. 2022. PMID: 35135702 No abstract available.
In search of perfection.
Gebel HM, Bray RA. Gebel HM, et al. Among authors: bray ra. Am J Transplant. 2013 Aug;13(8):1951-2. doi: 10.1111/ajt.12335. Epub 2013 Jul 9. Am J Transplant. 2013. PMID: 23837443 Free article. No abstract available.
906 results